CERo Therapeutics (CERO) Competitors $4.99 +0.11 (+2.25%) Closing price 04:00 PM EasternExtended Trading$5.02 +0.03 (+0.68%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. MURA, XCUR, JATT, RNXT, SCYX, HYPD, MDCX, THAR, DYAI, and RNTXShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Mural Oncology (MURA), Exicure (XCUR), JATT Acquisition (JATT), RenovoRx (RNXT), SCYNEXIS (SCYX), Hyperion DeFi (HYPD), Medicus Pharma (MDCX), Tharimmune (THAR), Dyadic International (DYAI), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors Mural Oncology Exicure JATT Acquisition RenovoRx SCYNEXIS Hyperion DeFi Medicus Pharma Tharimmune Dyadic International Rein Therapeutics CERo Therapeutics (NASDAQ:CERO) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the media favor CERO or MURA? In the previous week, CERo Therapeutics had 9 more articles in the media than Mural Oncology. MarketBeat recorded 10 mentions for CERo Therapeutics and 1 mentions for Mural Oncology. CERo Therapeutics' average media sentiment score of 0.31 beat Mural Oncology's score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CERo Therapeutics Neutral Mural Oncology Neutral Do institutionals and insiders have more ownership in CERO or MURA? 29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 12.7% of CERo Therapeutics shares are held by company insiders. Comparatively, 2.2% of Mural Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is CERO or MURA more profitable? CERo Therapeutics' return on equity of 0.00% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CERo TherapeuticsN/A N/A -209.40% Mural Oncology N/A -107.76%-87.57% Which has more volatility & risk, CERO or MURA? CERo Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Do analysts prefer CERO or MURA? CERo Therapeutics currently has a consensus target price of $45.00, suggesting a potential upside of 801.80%. Mural Oncology has a consensus target price of $12.00, suggesting a potential upside of 479.71%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CERo Therapeutics is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger earnings & valuation, CERO or MURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCERo TherapeuticsN/AN/A-$8.30MN/AN/AMural OncologyN/AN/A-$128.51M-$8.59-0.24 SummaryCERo Therapeutics beats Mural Oncology on 8 of the 11 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.88M$2.61B$5.83B$10.07BDividend YieldN/A48.62%5.25%4.53%P/E RatioN/A23.7375.5726.01Price / SalesN/A656.95536.77117.75Price / CashN/A169.9337.4259.95Price / Book-0.125.2711.536.20Net Income-$8.30M$32.95M$3.29B$270.65M7 Day Performance-31.17%1.34%0.44%2.77%1 Month Performance-37.23%30.71%10.84%8.83%1 Year Performance-97.33%2.03%61.62%27.49% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics4.0936 of 5 stars$4.99+2.3%$45.00+801.8%-97.6%$5.88MN/A0.008News CoverageShort Interest ↓MURAMural Oncology2.7129 of 5 stars$2.08+1.0%$12.00+476.9%-31.4%$35.69MN/A-0.24119XCURExicure1.8319 of 5 stars$5.47-2.5%N/A+139.9%$35.44M$500K-1.4150Gap DownJATTJATT AcquisitionN/A$2.04-3.8%N/A-39.0%$35.19MN/A0.003High Trading VolumeRNXTRenovoRx1.8984 of 5 stars$1.08+12.5%$7.50+594.4%+7.4%$35.18M$40K-2.846Short Interest ↑High Trading VolumeSCYXSCYNEXIS0.6807 of 5 stars$0.84+0.5%N/A-28.5%$34.86M$3.26M-2.0960Gap UpHYPDHyperion DeFi0.2525 of 5 stars$5.93-2.8%$2.00-66.3%-80.6%$34.74M$60K-0.1040News CoverageGap UpMDCXMedicus Pharma1.6704 of 5 stars$2.08+7.2%$23.50+1,029.8%N/A$34.56MN/A-1.55N/ATHARTharimmune2.976 of 5 stars$5.20-12.6%$17.00+226.9%-5.1%$33.86MN/A-0.852Positive NewsDYAIDyadic International3.1009 of 5 stars$0.95+3.3%$6.00+530.5%-20.9%$33.34M$3.42M-5.017Analyst ForecastShort Interest ↓RNTXRein TherapeuticsN/A$1.35-2.9%N/AN/A$32.39MN/A0.009Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies MURA Alternatives XCUR Alternatives JATT Alternatives RNXT Alternatives SCYX Alternatives HYPD Alternatives MDCX Alternatives THAR Alternatives DYAI Alternatives RNTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERO Stock Alerts